期刊
CANCER SCIENCE
卷 107, 期 3, 页码 326-334出版社
WILEY
DOI: 10.1111/cas.12880
关键词
Biomarker; breast cancer; cancer screening; liquid biopsy; microRNA
类别
资金
- New Energy and Industrial Technology Development Organization
- National Cancer Center Research and Development Fund [23-A-16, 23-A-21, 26-A-4]
- Ministry of Health, Labour and Welfare of Japan [14S-3, 14S-4, 17S-3, 17S-5, 20S-3, 20S-6]
- Japan Agency for Medical Research and Development
- Grants-in-Aid for Scientific Research [26860527] Funding Source: KAKEN
MicroRNA (miRNA), which are stably present in serum, have been reported to be potentially useful for detecting cancer. In the present study, we examined the expression profiles of serum miRNA in several large cohorts to identify novel miRNA that can be used to detect early stage breast cancer. We comprehensively evaluated the serum miRNA expression profiles using highly sensitive microarray analysis. A total of 1280 serum samples of breast cancer patients stored in the National Cancer Center Biobank were used. In addition, 2836 serum samples were obtained from non-cancer controls, 451 from patients with other types of cancers, and 63 from patients with non-breast benign diseases. The samples were divided into a training cohort including non-cancer controls, other cancers and breast cancer, and a test cohort including non-cancer controls and breast cancer. The training cohort was used to identify a combination of miRNA that could detect breast cancer, and the test cohort was used to validate that combination. miRNA expressions were compared between patients with breast cancer and non-breast cancer, and a combination of five miRNA (miR-1246, miR-1307-3p, miR-4634, miR-6861-5p and miR-6875-5p) was found to be able to detect breast cancer. This combination had a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% for breast cancer in the test cohort. In addition, this combination could detect early stage breast cancer (sensitivity of 98.0% for Tis).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据